TORONTO, Ontario, Canada and BENGALURU, Karnataka, India, June 27, 2025 (GLOBE NEWSWIRE) -- Biocon Biologics Ltd. (BBL), a ...

This approval paves the way for the launch of YESAFILI in Canada, scheduled for 04 July 2025. YESAFILI is the first ...

Biocon Biologics receives Health Canada approval for Yesafili, the first Eylea biosimilar in Canada, with launch slated for ...

Indian drugmaker Biocon has abandoned plans to market generic versions of Novo Nordisk’s hot-selling diabetes and weight-loss drugs in China due to local competition, a senior executive said. "We ...

Biocon Biologics receives Health Canada approval for its biosimilar Yesafili injection, used to treat various eye ailments.

Biocon Biologics secures Health Canada approval for Yesafili, the first biosimilar to Eylea® in Canada, with a global launch ...

Indian drugmaker Biocon has announced that Health Canada has granted a Notice of Compliance for Yesafili (aflibercept), a ...

Biotechnology firm Biocon Ltd on Thursday said its board has approved the acquisition of optionally convertible debentures of ...

Biocon’s growth story has long been muted — until now. With Viatris in its fold and a strong biosimilars pipeline, the ...

S&P says Biocon will bring down adjusted debt to Rs 20,000 crore by FY26 through equity issuance, with strong cash flows ...